BSE Live
Apr 21, 12:46Prev. Close
2143.60
Open Price
2160.55
Bid Price (Qty.)
2192.15 (2)
Offer Price (Qty.)
2194.70 (5)
NSE Live
Apr 21, 12:46Prev. Close
2144.00
Open Price
2150.00
Bid Price (Qty.)
2192.90 (35)
Offer Price (Qty.)
2194.20 (15)
| Profit & Loss account of Mankind Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 12,207.44 | 10,333.63 | 8,742.85 | 7,781.56 | 6,214.43 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 12,207.44 | 10,333.63 | 8,742.85 | 7,781.56 | 6,214.43 | |
| Total Operating Revenues | 12,207.44 | 10,334.77 | 8,749.43 | 7,781.56 | 6,214.43 | |
| Other Income | 536.79 | 280.86 | 128.57 | 196.03 | 170.95 | |
| Total Revenue | 12,744.23 | 10,615.63 | 8,878.00 | 7,977.58 | 6,385.38 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 2,016.35 | 1,853.52 | 1,813.66 | 2,057.56 | 1,373.18 | |
| Purchase Of Stock-In Trade | 1,655.69 | 1,409.85 | 809.24 | 813.75 | 654.83 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -183.00 | -53.67 | 290.74 | -449.59 | -247.40 | |
| Employee Benefit Expenses | 2,692.37 | 2,274.73 | 1,918.47 | 1,620.59 | 1,415.78 | |
| Finance Costs | 429.41 | 33.53 | 44.47 | 58.61 | 20.15 | |
| Depreciation And Amortisation Expenses | 621.22 | 398.25 | 325.92 | 166.62 | 118.97 | |
| Other Expenses | 3,008.10 | 2,315.28 | 2,016.68 | 1,749.88 | 1,352.23 | |
| Total Expenses | 10,240.14 | 8,231.49 | 7,219.18 | 6,017.43 | 4,705.45 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,504.09 | 2,384.14 | 1,658.81 | 1,960.15 | 1,679.93 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 2,504.09 | 2,384.14 | 1,658.81 | 1,960.15 | 1,679.93 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 596.04 | 492.58 | 327.56 | 469.03 | 396.17 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -86.30 | -35.00 | 34.01 | 52.61 | 2.41 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 509.74 | 457.59 | 361.56 | 521.64 | 398.58 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1,994.35 | 1,926.56 | 1,297.25 | 1,438.51 | 1,281.36 | |
| Profit/Loss From Continuing Operations | 1,994.35 | 1,926.56 | 1,297.25 | 1,438.51 | 1,281.36 | |
| Profit/Loss For The Period | 1,998.88 | 1,926.56 | 1,297.25 | 1,438.51 | 1,281.36 | |
| Minority Interest | -20.16 | -28.88 | -27.82 | -19.48 | -27.61 | |
| Consolidated Profit/Loss After MI And Associates | 1,990.96 | 1,912.90 | 1,281.86 | 1,433.48 | 1,265.43 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 49.00 | 48.00 | 32.00 | 36.00 | 32.00 | |
| Diluted EPS (Rs.) | 49.00 | 48.00 | 32.00 | 36.00 | 32.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
30.03.2026
17.02.2026
05.02.2026
Mankind Pharma Consolidated December 2025 Net Sales at Rs 3,567.20 crore, up 10.44% Y-o-Y
05.02.2026
Mankind Pharma Standalone December 2025 Net Sales at Rs 2,632.68 crore, up 9.85% Y-o-Y
05.02.2026
Mankind Pharma Consolidated December 2025 Net Sales at Rs 3,567.20 crore, up 10.44% Y-o-Y
05.02.2026
Mankind Pharma Standalone December 2025 Net Sales at Rs 2,632.68 crore, up 9.85% Y-o-Y
12.11.2025
Mankind Pharma Standalone September 2025 Net Sales at Rs 2,608.78 crore, up 3.12% Y-o-Y
07.11.2025
Mankind Pharma Consolidated September 2025 Net Sales at Rs 3,697.16 crore, up 20.17% Y-o-Y